DURHAM, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world's largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
DURHAM, N.C., March 18, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
DURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world™s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
DURHAM, N.C. and TOKYO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world™s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development...
DURHAM, N.C., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world™s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
Goldman Sachs™ Partner, Global co-Head of Private Equity Michael Bruun joins as new Director, succeeding current Goldman Sachs Board member Jo Natauri who is retiring from the firm at the end of the...
Parexel Teams with MyEyeDr. to Increase Patient Access and Participation in Ophthalmology Clinical Trials
BOSTON and DURHAM, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development...
Parexel, a clinical research organisation (CRO), announced the launch of its Community Alliance Network, a program integrating clinical research into the community healthcare setting to better serve patients and create opportunities for increased diversity in clinical trials. CVS Health, a health care solutions company, and Javara, an integrated research organisation, have joined the network as inaugural members, to support trial delivery for Parexel’s biopharma customers.
BOSTON, and DURHAM, N.C., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, has been ranked as the “Top CRO to Work With” by investigative sites in the 2021 WCG CenterWatch Global Site Relationship Benchmark Survey. The biannual WCG CenterWatch survey explores the relationships among clinical trial sites and their sponsors and CROs and provides insight into overall performance. Highlights from the survey were published earlier today by CenterWatch in a press release available here.